Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Felzartamab in Kidney Transplants With Late Isolated Microvascular Inflammation
NCT07219043Phase 2Recruiting
- Sponsor
- Biogen
- Start
- Jan 2026
- Primary completion
- Feb 2028
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of felzartamab in microvascular inflammation (MVI), sponsored by Biogen. Started Jan 2026; status: recruiting.
02
Drugs
felzartamab
03
Conditions
microvascular inflammation (MVI)
Beyond the preview
Go deeper on NCT07219043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07219043.